文献
J-GLOBAL ID:201402225364868760
整理番号:14A0588827
治験薬のCYP3A阻害能をリスク評価するのに用いるさまざまな静的in vitro-in vivo外挿モデルの評価
Evaluation of Various Static In Vitro-In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug
著者 (25件):
VIEIRA Md L T
(US Food and Drug Administration, MD, USA)
,
KIRBY B
(Univ. of Washington, WA, USA)
,
RAGUENEAU-MAJLESSI I
(Univ. of Washington, WA, USA)
,
GALETIN A
(Univ. of Manchester, Greater Manchester, GBR)
,
CHIEN J Y L
(Eli Lilly and Co., IN, USA)
,
EINOLF H J
(Novartis, NJ, USA)
,
FAHMI O A
(Pfizer Inc., CT, USA)
,
FISCHER V
(AbbVie, IL, USA)
,
FRETLAND A
(Eli Lilly and Co., IN, USA)
,
GRIME K
(AstraZeneca Res. and Dev., Moelndal, SWE)
,
HALL S D
(Eli Lilly and Co., IN, USA)
,
HIGGS R
(Eli Lilly and Co., IN, USA)
,
PLOWCHALK D
(Pfizer Inc., CT, USA)
,
RILEY R
(AstraZeneca Res. and Dev., Alderley Park, GBR)
,
SEIBERT E
(Boehringer Ingelheim Pharmaceuticals, CT, USA)
,
SKORDOS K
(Res. Triangle Park, NC, USA)
,
SNOEYS J
(Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, BEL)
,
VENKATAKRISHNAN K
(Millennium Pharmaceuticals, MA, USA)
,
WATERHOUSE T
(Eli Lilly and Co., IN, USA)
,
OBACH R S
(Pfizer Inc., CT, USA)
,
BERGLUND E G
(Medical Products Agency, Uppsala, SWE)
,
ZHANG L
(US Food and Drug Administration, MD, USA)
,
ZHAO P
(US Food and Drug Administration, MD, USA)
,
REYNOLDS K S
(US Food and Drug Administration, MD, USA)
,
HUANG S-M
(US Food and Drug Administration, MD, USA)
資料名:
Clinical Pharmacology & Therapeutics
(Clinical Pharmacology & Therapeutics)
巻:
95
号:
2
ページ:
189-198
発行年:
2014年02月
JST資料番号:
A0721B
ISSN:
0009-9236
資料種別:
逐次刊行物 (A)
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)